Eli Lilly's new vials of Zepbound aim to improve accessibility by selling starter doses directly online, pricing them significantly below competitors, amid ongoing shortages.
This new initiative by Lilly is expected to ease the supply bottleneck caused by the demand for auto-injector pens, as it prepares the market for wider access.
Lilly's president stressed that the launch of these vials will greatly enhance the availability of Zepbound in the U.S., addressing both demand and supply issues.
Analyst Daniel Grosslight noted that Lilly's vials could capture market share from compounded medications, which have become more popular due to shortages of established brands.
Collection
[
|
...
]